Replication-competent herpes simplex vectors: Design and applications

Gene Therapy

Volumn 12, Issue , 2005, Pages S170-S177

  Argnani, R ^a   Lufino, M ^a   Manservigi, M ^a   Manservigi, R ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

HSV; Targeting; Tumors; Viral vectors

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOSINE DEAMINASE; ERYTHROPOIETIN; FLUOROURACIL; GANCICLOVIR; GENE PRODUCT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERPES SIMPLEX VACCINE; HERPESVIRUS VECTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13 RECEPTOR ALPHA2; INTERLEUKIN 4; MEMBRANE PROTEIN; RIBONUCLEOTIDE REDUCTASE; THYMIDINE KINASE; VIRUS PROTEIN;

CANCER CELL; CELL CULTURE; CELL DESTRUCTION; CELL LINE; CONFERENCE PAPER; GENE DELETION; GENE EXPRESSION; GENE EXPRESSION SYSTEM; GENETIC ENGINEERING; GIBBON LEUKEMIA VIRUS; GOOD CLINICAL PRACTICE; GOOD MANUFACTURING PRACTICE; HEALTH CARE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; IN VITRO STUDY; INFECTION PREVENTION; NERVOUS SYSTEM; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM; VIROGENESIS; VIRUS ATTENUATION; VIRUS MUTATION; VIRUS REPLICATION; VIRUS VIRULENCE;

ANIMALS; CANCER VACCINES; GENE TARGETING; GENE THERAPY; GENETIC ENGINEERING; HUMANS; IMMUNIZATION; NEOPLASMS; PERIPHERAL NERVOUS SYSTEM; PERIPHERAL NERVOUS SYSTEM DISEASES; SIMPLEXVIRUS; VIRAL VACCINES; VIRUS REPLICATION;

GIBBON APE LEUKEMIA VIRUS; HERPES; HERPESVIRIDAE; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2; SIMPLEXVIRUS;

EID: 27544463977     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302622     Document Type: Article

References (78)

1. Roizman B, Knipe DM. Herpes simplex viruses and their replication. In: Knipe DM, Howley PM (eds). Fields Virology. Lippincot, Williams and Wilkins: Philadelphia, PA, 2001, pp 2399-2460.
2. Todo T. Oncolytic virus therapy using genetically engineered herpes simplex viruses. Hum Cell 2002; 15: 151-159.
3. Hu JC, Coffin RS. Oncolytic herpes simplex virus for tumor therapy. Int Rev Neurobiol 2003; 55: 165-184.
4. Chiocca EA. Oncolytic viruses. Nat Rev Cancer 2002; 2: 938-950.
5. Mullen JT, Tanabe KK. Viral oncolysis. Oncologist 2002; 7: 106-119.
6. Shah AC, Benos D, Gillespie GY, Markert JM. Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas. J Neurooncol 2003; 65: 203-226.
7. Post DE, Fulci G, Chiocca EA, Van Meir EG. Replicative oncolytic herpes simplex viruses in combination cancer therapies. Curr Gene Ther 2004; 4: 41-51.
8. Spector FC et al. Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs. J Infect Dis 1998; 177: 1143-1154.
9. Koelle DM, Corey L. Recent progress in herpes simplex virus immunobiology and vaccine research. Clin Microbiol Rev 2003; 16: 96-113.
10. Morrison LA. Vaccines against genital herpes: progress and limitations. Drugs 2002; 62: 1119-1129.
11. De Giuli Morghen C et al. Virus vectors for immunoprophylaxis. AIDS Rev 2000; 2: 127-135.
12. Meignier B, Longnecker R, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J Infect Dis 1988; 158: 602-614.
13. Meignier B, Martin B, Whitley RJ, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J Infect Dis 1990; 162: 313-321.
14. Bernstein DI, Ireland J, Bourne N. Pathogenesis of acyclovir- resistant herpes simplex type 2 isolates in animal models of genital herpes: models for antiviral evaluations. Antiviral Res 2000; 47: 159-169.
15. Walker J, Leib DA. Protection from primary infection and establishment of latency by vaccination with a herpes simplex virus type 1 recombinant deficient in the virion host shutoff (vhs) function. Vaccine 1998; 16: 1-5.
16. Aurelian L, Kokuba H, Smith CC. Vaccine potential of a herpes simplex virus type 2 mutant deleted in the PK domain of the large subunit of ribonucleotide reductase (ICP10). Vaccine 1999; 17: 1951-1963.
17. Galanis E, Vile R, Russell SJ. Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors. Crit Rev Oncol Hematol 2001; 38: 177-192.
18. Markert JM, Parker JN, Gillespie GY, Whitley RJ. Genetically engineered human herpes simplex virus in the treatment of brain tumours. Herpes 2001; 8: 17-22.
19. Toda M, Rabkin SD, Kojima H, Martuza RL. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther 1999; 10: 385-393.
20. Toda M, Martuza RL, Rabkin SD. Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor. Mol Ther 2000; 2: 324-329.
21. Todo T, Martuza RL, Rabkin SD, Johnson PA. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA 2001; 98: 6396-6401.
22. Boviatsis EJ et al. Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. Gene Therapy 1994; 1: 323-331.
23. Martuza RL et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991; 252: 854-856.
24. Kramm CM et al. Long-term survival in a rodent model of disseminated brain tumors by combined intrathecal delivery of herpes vectors and ganciclovir treatment. Hum Gene Ther 1996; 7: 1989-1994.
25. Carroll NM, Chase M, Chiocca EA, Tanabe KK. The effect of ganciclovir on herpes simplex virus-mediated oncolysis. J Surg Res 1997; 69: 413-417.
26. Chambers R et al. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc Natl Acad Sci USA 1995; 92: 1411-1415.
27. Markert JM, Malick A, Coen DM, Martuza RL. Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery 1993; 32: 597-603.
28. Chou J, Kern ER, Whitley RJ, Roizman B. Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 1990; 250: 1262-1266.
29. Liu BL et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Therapy 2003; 10: 292-303.
30. Mineta T et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995; 1: 938-943.
31. Hunter WD et al. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. J Virol 1999; 73: 6319-6326.
32. Markert JM et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Therapy 2000; 7: 867-874.
33. MacLean AR et al. Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence. J Gen Virol 1991; 72 (Part 3): 631-639.
34. Harrow S et al. HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Therapy 2004; 11: 1648-1658.
35. Rampling R et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Therapy 2000; 7: 859-866.
36. Randazzo BP et al. Treatment of experimental intracranial murine melanoma with a neuroattenuated herpes simplex virus 1 mutant. Virology 1995; 211: 94-101.
37. Toda M, Rabkin SD, Martuza RL. Treatment of human breast cancer in a brain metastatic model by G207, a replication- competent multimutated herpes simplex virus 1. Hum Gene Ther 1998; 9: 2177-2185.
38. Kooby DA et al. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J 1999; 13: 1325-1334.
39. Cozzi PJ et al. Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses. Prostate 2002; 53: 95-100.
40. McAuliffe PF et al. Effective treatment of pancreatic tumors with two multimutated herpes simplex oncolytic viruses. J Gastrointest Surg 2000; 4: 580-588.
41. Carew JF et al. Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207). Hum Gene Ther 1999; 10: 1599-1606.
42. Andreansky S et al. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Therapy 1998; 5: 121-130.
43. Parker JN et al. Engineered herpes simplex virus expressing IL-in the treatment of experimental murine brain tumors. Proc Natl Acad Sci USA 2000; 97: 2208-2213.
44. Bennett JJ et al. Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer. Ann Surg 2001; 233: 819-826.
45. Wong RJ et al. Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Hum Gene Ther 2001; 12: 253-265.
46. Todo T, Martuza RL, Dallman MJ, Rabkin SD. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity. Cancer Res 2001; 61: 153-161.
47. Nakamura H et al. Multimodality therapy with a replication- conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocyto- sine to 5-fluorouracil. Cancer Res 2001; 61: 5447-5452.
48. Aghi M et al. Synergistic anticancer effects of ganciclovirl thymidine kinase and 5-fluorocytosinelcytosine deaminase gene therapies. J Natl Cancer Inst 1998; 90: 370-380.
49. Toda M, Martuza RL, Rabkin SD. Combination suicidelcytokine gene therapy as adjuvants to a defective herpes simplex virus- based cancer vaccine. Gene Therapy 2001; 8: 332-339.
50. Pawlik TM et al. Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene. Cancer 2002; 95: 1171-1181.
51. Aghi M et al. Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorinel rat cytochrome P450 2B1 and ganciclovirlherpes simplex virus thymidine kinase gene therapies. Cancer Res 1999; 59: 3861-3865.
52. Mohr I et al. A herpes simplex virus type 1 gamma34.5 second- site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals. J Virol 2001; 75: 5189-5196.
53. He B et al. Suppression of the phenotype of gamma(1)34.5- herpes simplex virus 1: failure of activated RNA-dependent protein kinase to shut off protein synthesis is associated with a deletion in the domain of the alpha47 gene. J Virol 1997; 71: 6049-6054.
54. Taneja S et al. Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells. Proc Natl Acad Sci USA 2001; 98: 8804-8808.
55. Chahlavi A, Todo T, Martuza RL, Rabkin SD. Replication- competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia 1999; 1: 162-169.
56. Jorgensen TJ et al. Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer. Neoplasia 2001; 3: 451-456.
57. Fu X, Zhang X. Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype. Cancer Res 2002; 62: 2306-2312.
58. Fu X et al. Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect. Mol Ther 2003; 7: 748-754.
59. Nakamori M, Fu X, Pettaway CA, Zhang X. Potent antitumor activity after systemic delivery of a doubly fusogenic oncolytic herpes simplex virus against metastatic prostate cancer. Prostate 2004; 60: 53-60.
60. Laquerre S et al. Heparan sulfate proteoglycan binding by herpes simplex virus type 1 glycoproteins B and C, which differ in their contributions to virus attachment, penetration, and cell-to-cell spread. J Virol 1998; 72: 6119-6130.
61. Laquerre S, Anderson DB, Stolz DB, Glorioso JC. Recombinant herpes simplex virus type 1 engineered for targeted binding to erythropoietin receptor-bearing cells. J Virol 1998; 72: 9683-9697.
62. Argnani R, Boccafogli L, Marconi PC, Manservigi R. Specific targeted binding of herpes simplex virus type 1 to hepatocytes via the human hepatitis B virus preS1 peptide. Gene Therapy 2004; 11: 1087-1098.
63. Anderson DB et al. Pseudotyping of glycoprotein D-deficient herpes simplex virus type 1 with vesicular stomatitis virus glycoprotein G enables mutant virus attachment and entry. J Virol 2000; 74: 2481-2487.
64. Zhou G, Ye GJ, Debinski W, Roizman B. Engineered herpes simplex virus 1 is dependent on IL13Ralpha 2 receptor for cell entry and independent of glycoprotein D receptor interaction. Proc Natl Acad Sci USA 2002; 99: 15124-15129.
65. Manoj S et al. Mutations in herpes simplex virus glycoprotein D that prevent cell entry via nectins and alter cell tropism. Proc Natl Acad Sci USA 2004; 101: 12414-12421.
66. Boviatsis EJ et al. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res 1994; 54: 5745-5751.
67. Miyatake S, Iyer A, Martuza RL, Rabkin SD. Transcriptional targeting of herpes simplex virus for cell-specific replication. J Virol 1997; 71: 5124-5132.
68. Yamamura H et al. Identification of the transcriptional regulatory sequences of human calponin promoter and their use in targeting a conditionally replicating herpes vector to malignant human soft tissue and bone tumors. Cancer Res 2001; 61: 3969-3977.
69. Mullen JT et al. Regulation of herpes simplex virus 1 replication using tumor-associated promoters. Ann Surg 2002; 236: 502-512; discussion 512-513.
70. Chung RY, Saeki Y, Chiocca EA. B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells. J Virol 1999; 73: 7556-7564.
71. Hernandez-Alcoceba R, Pihalja M, Qian D, Clarke MF. New oncolytic adenoviruses with hypoxia- and estrogen receptor- regulated replication. Hum Gene Ther 2002; 13: 1737-1750.
72. Marples B et al. Development of synthetic promoters for radiation-mediated gene therapy. Gene Therapy 2000; 7: 511-517.
73. Scott SD, Marples B. Radiation-activated antitumor vectors. Methods Mol Med 2004; 90: 389-402.
74. Palmer JA et al. Development and optimization of herpes simplex virus vectors for multiple long-term gene delivery to the peripheral nervous system. J Virol 2000; 74: 5604-5618.
75. Braz J et al. Therapeutic efficacy in experimental polyarthritis of viral-driven enkephalin overproduction in sensory neurons. J Neurosci 2001; 21: 7881-7888.
76. Liu X et al. Herpes simplex virus mediated gene transfer to primate ocular tissues. Exp Eye Res 1999; 69: 385-395.
77. Spencer B et al. Herpes simplex virus-mediated gene delivery to the rodent visual system. Invest Ophthalmol Vis Sci 2000; 41: 1392-1401.
78. Goins WF et al. Herpes simplex virus type 1 vector-mediated expression of nerve growth factor protects dorsal root ganglion neurons from peroxide toxicity. J Virol 1999; 73: 519-532.